Rockefeller Capital Management L.P. Fate Therapeutics Inc Transaction History

Rockefeller Capital Management L.P.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 02, 2022	SELL	$21.04 - $36.06 $715 - $1,226	-34 Reduced 89.47%	4 $0
Q2 2022 Aug 12, 2022	SELL	$17.78 - $42.39 $1,315 - $3,136	-74 Reduced 66.07%	38 $0
Q1 2022 May 13, 2022	BUY	$29.67 - $60.28 $3,085 - $6,269	104 Added 1300.0%	112 $4,000
Q4 2021 Feb 14, 2022	BUY	$47.84 - $64.34 $382 - $514	8 New	8 $0
Q3 2021 Nov 12, 2021	SELL	$59.27 - $95.73 $474 - $765	-8 Closed	0 $0
Q2 2021 Aug 10, 2021	BUY	$67.25 - $92.52 $538 - $740	8 New	8 $0

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $222M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Rockefeller Capital Management L.P., based on Form 13F filings with the SEC.

Stay updated on Rockefeller Capital Management L.P. with notifications on news.